Results 211 to 220 of about 4,101 (234)
Some of the next articles are maybe not open access.
[Immune Reconstitution after BTKi Treatment in Chronic Lymphocytic Leukemia].
Zhongguo shi yan xue ye xue za zhiTo analyze the immune reconstitution after BTKi treatment in patients with chronic lymphocytic leukemia (CLL).The clinical and laboratorial data of 59 CLL patients admitted from January 2017 to March 2022 in Fujian Medical University Union Hospital were collected and analyzed retrospectively.The median age of 59 CLL patients was 60.5(36-78).
Yuan-Li, Wang +7 more
openaire +1 more source
Paul J. Hampel, Sameer A. Parikh
openaire +2 more sources
EXABS-124-CLL Extended Abstract: New BTKi
Clinical Lymphoma Myeloma and Leukemia, 2022openaire +1 more source
BTKi, venetoclax, obinutuzumab: what is the ideal combination?
memo - Magazine of European Medical Oncology, 2021openaire +1 more source
HARNESSING BTKI THERAPY BY CDK4/6I CONTROL OF T CELL SURVEILLANCE
Hematological Oncology, 2023S. Chen‐Kiang +5 more
openaire +1 more source
CARDIOTOXICITY FROM BRUTON TYROSINE KINASE INHIBITORS (BTKI) - AN ANALYSIS OF OPTUM DATABASE
Journal of the American College of Cardiology, 2023Srilakshmi Vallabhaneni +4 more
openaire +1 more source
Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
Blood Advances, 2022Elizabeth Brem, Susan M O'brien
exaly
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
International Journal of Molecular Sciences, 2020Maissa Mhibik +2 more
exaly
BTKi-Therapie bei CLL: Die MFA als Förder:innen der Adhärenz
CNE Pflegemanagement, 2022openaire +1 more source